title: A Plethora of GLP-1 Agonists: Decisions About What to Use and When.
abstract: Incretin-based therapies are important addition to our armamentarium for the treatment of type 2 diabetes (T2DM). There are six Glucagon-like peptide-1 receptor agonists (GLP-1RAs) which have received regulatory approval for clinical use. The short-acting GLP-1RAs include exenatide twice daily, liraglutide once daily, and lixisenatide once daily. The approved long-acting GLP-1RAs are administered weekly and are exenatide, albiglutide, and dulaglutide. Although all of these therapies lower hemoglobin A1C (HbA1C), there also are unique features of GLP-1RAs that have been made manifest from clinical trial data with regard to weight-loss efficacy, fasting and post-prandial glucose control, cardiovascular safety and protection, and gastrointestinal and injection adverse effects. It is imperative to consider these features when tailoring the choice of a GLP-1RA to patient specific characteristics.
authors.affiliation: Department of Medicine, Baylor College of Medicine, One Baylor Plaza, ABBR R615, Houston, TX, 77030, USA. ssamson@bcm.edu.
authors.forename: Susan L
authors.initials: SL
authors.lastname: Samson
authors.affiliation: Departments of Medicine, Molecular and Cellular Biology, Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, BCM 620, Houston, TX, 77030, USA.
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Garber
mesh_terms: D006801:Humans; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D000077270:Exenatide; D004763:Glucagon-Like Peptides / Q000031:analogs & derivatives; D006442:Glycated Hemoglobin / Q000032:analysis; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007141:Immunoglobulin Fc Fragments / Q000009:adverse effects / Q000627:therapeutic use; D000069450:Liraglutide / Q000009:adverse effects / Q000627:therapeutic use; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D014688:Venoms / Q000009:adverse effects / Q000627:therapeutic use; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: C555680:dulaglutide; D000077270:Exenatide; D004763:Glucagon-Like Peptides; D006442:Glycated Hemoglobin; C517652:hemoglobin A1c protein, human; D007004:Hypoglycemic Agents; D007141:Immunoglobulin Fc Fragments; D000069450:Liraglutide; D010455:Peptides; D011993:Recombinant Fusion Proteins; D014688:Venoms; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
keywords: Diabetes prevention; Impaired fasting glucose; Impaired glucose tolerance; Obesity; Pre-diabetes; Type 2 diabetes; Weight loss